Benzinga · Jul 10, 2026
Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover
Private equity giants circle Qiagen (QGEN) with potential bids of $50/share. Get the details on the molecular diagnostics buyout.
MA
NASDAQ · MASI
Masimo Corporation
Healthcare · Medical - Instruments & Supplies
$179.95
Up+$0.00 (+0.00%)
Updated Sep 16, 2026, 4:39 AM
SID Score
6.1/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 7.63B
- P/E ratio
- -13.4
- Dividend yield
- 0.00%
- 52-week range
- $125.94 – $179.99
- Volume
- 3.16M
- Avg. volume
- 743.98K
Price performance
MASI price history
1M range · 0 trading sessions · Daily adjusted prices
MASI does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest MASI news
The latest Smart Investors Daily articles mentioning MASI.
Stock researchCompany · Overview
MASI research
Overview
Company profile and research snapshot.
Company profile
Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $195.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 27, 2026 | Raymond James | Market Perform | — |
| Feb 18, 2026 | Wells Fargo | Equal-Weight | — |
| Feb 18, 2026 | BTIG | Neutral | — |
| Dec 4, 2025 | BTIG | Buy | — |
| Nov 24, 2025 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Jun 11, 2026
ResMed: GLP-1 Threats Are Overstated
ResMed's GLP-1 concerns are overstated, and though a portion of market share will be lost, the remaining portion will be more beneficial to profitability. Learn more about RMD stock here.
Yahoo · Jun 10, 2026
Danaher Closes Acquisition of Masimo; Maintains Q2, 2026 Outlook
Danaher (DHR) said Wednesday it has completed its acquisition of Masimo (MASI), a speciality diagnos
Yahoo · Jun 10, 2026
Danaher Completes Acquisition of Masimo Corporation
Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has completed the acquisition of Masimo Corporation, a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
